Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Noxopharm Ltd. ( (AU:NOX) ) just unveiled an update.
Noxopharm has engaged global clinical research organisation Novotech to support preparations for a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration for its SOF-SKN candidate, part of the Sofra technology platform. The collaboration aims to refine the data package, clinical development pathway and manufacturing and quality plans needed to advance SOF-SKN into an IND application.
Management believes that progressing to a successful IND would materially enhance the commercial appeal of SOF-SKN and the broader Sofra platform to potential partners in the U.S. and other markets. SOF-SKN is initially being developed for chronic inflammation associated with cutaneous lupus erythematosus, a market estimated at more than US$3.3 billion and expected to grow, with potential expansion into other autoimmune skin diseases and immune-related conditions, underscoring Noxopharm’s efforts to strengthen its regulatory footing and industry positioning in high-growth autoimmune segments.
More about Noxopharm Ltd.
Noxopharm Limited is a clinical-stage Australian biotechnology company focused on developing novel treatments for cancer and inflammatory and autoimmune diseases, including technologies to improve the safety profile of mRNA medicines. Its pipeline is built around two proprietary platforms, Sofra for inflammation, autoimmunity, mRNA enhancement and oncology, and Chroma for oncology, targeting large and growing global markets in autoimmune disease therapeutics and immuno-oncology.
The Sofra technology platform is based on short nucleic acid sequences, or oligonucleotides, that act on specific immune sensors to regulate inflammation at its source by either reducing or stimulating immune responses. Sofra underpins candidates such as SOF-SKN for cutaneous lupus erythematosus and other autoimmune-related skin diseases, and has potential applications in conditions including rheumatoid arthritis, lupus, diabetes and certain cancers, positioning Noxopharm in multiple high-value therapeutic segments.
Average Trading Volume: 168,405
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$21.81M
Learn more about NOX stock on TipRanks’ Stock Analysis page.